HEALTHCNBC TOP
Healthy Returns: Employers aren't expanding coverage of GLP-1 obesity drugs – many are finding ways around it
Approximately 36% of employers provide coverage for GLP-1 obesity drugs for both diabetes and weight loss in 2025, unchanged from the previous year and up from 34% in 2024. Many employers are finding ways to avoid expanding this coverage.
Related Signal
Adjacent reporting
- STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more
- Restrictions on obesity drug coverage force patients to pivot
- Some U.S. employers are dropping weight loss drug coverage as use surges
- Trouble Getting Weight Loss Drugs Covered by Insurance? Here’s What To Know
- CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans
- Want obesity drugs covered by insurance? Telehealth companies have a big say